Balashova T S, Golega E N, Rud'ko I A, Balabolkin M I, Kubatiev A A
Ter Arkh. 1993;65(10):23-7.
The study included 16 patients with diabetes mellitus (DM) type 1 and 15 healthy controls. By the moment of examination the patients had achieved subcompensation. 10 patients developed diabetic vascular complications. The patients received biosynthetic insulins Humulin S, Humulin I, Humulin M3. Pretreatment glycemia in the patients surpassed that in the controls, MDA red cell levels per ml of hemolysate were higher by 121% and 130% per protein 1 mg. MDA measured equal both in angiopathy patients and those without it. The activity of the antioxidant enzymes in DM patients was similar to control indices. Human insulin administration reduced red cell MDA levels both in angiopathy and free of it patients, though in the former MDA remained higher than normal, while in the latter normal levels are obtained. The parameters of the antioxidant defense enzymes changed on the treatment week 12: catalase activity rose by 41%, that of superoxide dismutase and glutathione peroxidase lowered by 35 and 65%, respectively. Variations in these enzymes activity showed no dependence on vascular complications.
该研究纳入了16例1型糖尿病(DM)患者和15名健康对照者。在检查时,患者已达到代偿不全状态。10例患者出现了糖尿病血管并发症。患者接受了生物合成胰岛素优泌林S、优泌林I、优泌林M3治疗。患者治疗前的血糖水平高于对照组,每毫升溶血产物中红细胞丙二醛(MDA)水平按每毫克蛋白质计算分别高出121%和130%。有血管病变和无血管病变患者的MDA测量值相等。糖尿病患者抗氧化酶的活性与对照指标相似。使用人胰岛素后,有血管病变和无血管病变患者的红细胞MDA水平均降低,不过前者的MDA仍高于正常水平,而后者则达到了正常水平。抗氧化防御酶的参数在治疗第12周时发生了变化:过氧化氢酶活性上升了41%,超氧化物歧化酶和谷胱甘肽过氧化物酶的活性分别降低了35%和65%。这些酶活性的变化与血管并发症无关。